A5052056526- T-cell and B-cell Immunology
- Immune Cell Function and Interaction
- Immune Response and Inflammation
- Transplantation: Methods and Outcomes
- Psoriasis: Treatment and Pathogenesis
- Prostate Cancer Treatment and Research
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Receptor Mechanisms and Signaling
- IL-33, ST2, and ILC Pathways
- Chemokine receptors and signaling
- Cancer, Stress, Anesthesia, and Immune Response
- Immune cells in cancer
- Immunotherapy and Immune Responses
- Asthma and respiratory diseases
- Dermatology and Skin Diseases
- Radiopharmaceutical Chemistry and Applications
- Medical Imaging Techniques and Applications
- Glycosylation and Glycoproteins Research
- Cancer, Hypoxia, and Metabolism
- Eosinophilic Disorders and Syndromes
- Cell Adhesion Molecules Research
- Cancer Immunotherapy and Biomarkers
- Cytomegalovirus and herpesvirus research
- Epigenetics and DNA Methylation
- Adrenal Hormones and Disorders
Institute of Oncology Research
2021-2025
IRCCS Humanitas Research Hospital
2025
University Hospital of Zurich
2016-2023
IRCCS Ospedale San Raffaele
2020
University of Zurich
2016
Abstract Comprehensive genomic studies have delineated key driver mutations linked to disease progression for most cancers. However, corresponding transcriptional changes remain largely elusive because of the bias associated with cross-study analysis. Here, we overcome these hurdles and generate a comprehensive prostate cancer transcriptome atlas that describes roadmap tumor in qualitative quantitative manner. Most cancers follow uniform trajectory characterized by upregulation...
Abstract Transplantation of solid organs can be life-saving in patients with end-stage organ failure, however, graft rejection remains a major challenge. In this study, by pre-conditioning interleukin-2 (IL-2)/anti-IL-2 antibody complex treatment biased toward IL-2 receptor α, we achieved acceptance fully mismatched orthotopic lung allografts that remained morphologically and functionally intact for more than 90 days immunocompetent mice. These are tolerated the actions forkhead box p3...
Abstract Patients with metastatic castration-resistant prostate cancer (mCRPC) who progress on androgen deprivation therapy (ADT) have limited therapeutic options. Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein highly expressed in mCRPC and validated target for precision medicine approaches. TD001 novel antibody-drug conjugate (ADC) composed of deimmunized anti-PSMA IgG1 monoclonal antibody (HuJ591) conjugated to stable protease-cleavable topoisomerase I...
Prostate-specific membrane antigen (PSMA), a type II transmembrane glycoprotein folate receptor, is highly expressed in metastatic castrate-resistant prostate cancer (CRPC) and expression increases following androgen deprivation therapy. TD001 novel antibody-drug conjugate (ADC) composed of deimmunized anti-PSMA IgG1 monoclonal antibody (HuJ591), conjugated to stable, protease-cleavable proprietary Topo I inhibitor exatecan linker-payload (LD038), with drug-to-antibody ratio (DAR) 8. Free...
Abstract Prostate-specific membrane antigen (PSMA), a type II transmembrane glycoprotein belonging to the folate receptor family, is highly expressed in metastatic castration-resistant prostate cancer (mCRPC), and increases following androgen deprivation therapy (ADT). PSMA validated diagnostic therapeutic target for radioligands antibody-drug conjugates (ADCs). TD001 novel ADC composed of deimmunized anti-PSMA IgG1 monoclonal antibody (HuJ591) conjugated stable protease-cleavable...
Abstract Prostate-specific membrane antigen (PSMA), a type II transmembrane glycoprotein belonging to the folate receptor family, is highly expressed in metastatic castrate-resistant prostate cancer (CRPC), and increases following androgen deprivation therapy. TD001 novel antibody-drug conjugate (ADC) composed of deimmunized anti-PSMA IgG1 monoclonal antibody (HuJ591), which binds extracellular domain PSMA, conjugated proprietary cleavable topoisomerase I inhibitor exatecan linker-payload...
Abstract Background Systemic sclerosis (SSc) is a multiorgan autoimmune disease characterized by inflammation, vascular modification, and progressive fibrosis of the skin several visceral organs. Innate adaptive immune cells, including myeloid, B T are believed to be central pathogenesis SSc. However, role functional state neutrophil granulocytes (neutrophils) ill‐defined in Methods We performed prospective study neutrophils freshly isolated from SSc patients healthy donors (HD) measuring...
Regulation of neutrophil chemotaxis and activation plays crucial roles in immunity, dysregulated responses can lead to pathology as seen neutrophilic asthma. Neutrophil recruitment is key for initiating immune defense inflammation, its modulation a promising therapeutic target. Microfluidic technology an attractive tool characterization migration. Compared transwell assays, microfluidic approaches could offer several advantages, including precis e control defined chemokine gradients space...
<h3>Background</h3> Decreased number or altered function of regulatory T cells (Tregs) has been reported in many inflammatory rheumatic diseases, and Tregs are considered promising therapeutic targets for autoimmune diseases. It is thus high importance to delineate the pathways controlling biology onset autoimmunity. Fra2 a transcription factor belonging Fos family proteins which takes part AP-1 complex. The role so far unknown. <h3>Objectives</h3> To characterize potential autoimmunity...
<h3>Background</h3> Fos-related antigen 2 (Fra2) is a transcription factor belonging to the Fos family proteins which part of AP-1 complex. We recently described Fra2 transgenic (tg) mouse model develops multi-organ inflammatory phenotype affecting skin, lungs, thymus, liver and salivary glands. have observed abnormalities in T cell compartment, particularly regulatory (Treg) cells, led us hypothesize that tg mice develop driven autoimmune phenotype. <h3>Objectives</h3> To demonstrate...
Transplant (Tx) tolerance is a state of anergy by the recipient to Tx-related alloantigen. Lung allo-Tx has worst allograft survival outcome when compared all other transplantable solid organs. Interleukin (IL-) 2 promotes rejection through enhanced T cell-cytotoxicity. However, binding IL-2 in complex (cplx) with neutralizing anti-IL-2 antibody, it can induce expansion regulatory (Treg) cells. We therefore evaluated here impact on cplx experimental mouse lung Tx outcome.